Infectious burden and cognitive function: the Northern Manhattan Study by Katan, Mira et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Infectious burden and cognitive function: the Northern Manhattan Study
Katan, Mira; Moon, Yeseon Park; Paik, Myunghee Cho; Sacco, Ralph L; Wright, Clinton B; Elkind,
Mitchell S V
Abstract: OBJECTIVE: We hypothesized that infectious burden (IB), a composite serologic measure
of exposure to common pathogens (i.e., Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus,
and herpes simplex virus 1 and 2) associated with vascular risk in the prospective Northern Manhattan
Study (NOMAS), would also be associated with cognition. METHODS: Cognition was assessed using
the Mini-Mental State Examination (MMSE) at enrollment and the modified Telephone Interview for
Cognitive Status (TICS-m) at annual follow-up visits. Adjusted linear and logistic regressions were used
to measure the association between IB index and MMSE. Generalized estimating equation models were
used to evaluate associations with TICS-m and its change over time. RESULTS: Serologies and cognitive
assessments were available in 1,625 participants of the NOMAS cohort. In unadjusted analyses, higher
IB index was associated with worse cognition (change per standard deviation [SD] of IB for MMSE
was -0.77, p < 0.0001, and for first measurements of TICS-m was -1.89, p < 0.0001). These effects
were attenuated after adjusting for risk factors (for MMSE adjusted change per SD of IB = -0.17, p =
0.06, for TICS-m adjusted change per SD IB = -0.68, p < 0.0001). IB was associated with MMSE ￿24
(compared to MMSE >24, adjusted odds ratio 1.26 per SD of IB, 95% confidence interval 1.06-1.51).
IB was not associated with cognitive decline over time. The results were similar when IB was limited
to viral serologies only. CONCLUSION: A measure of IB associated with stroke risk and atherosclerosis
was independently associated with cognitive performance in this multiethnic cohort. Past infections may
contribute to cognitive impairment.
DOI: 10.1212/WNL.0b013e3182896e79
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-117229
Published Version
Originally published at:
Katan, Mira; Moon, Yeseon Park; Paik, Myunghee Cho; Sacco, Ralph L; Wright, Clinton B; Elkind,
Mitchell S V (2013). Infectious burden and cognitive function: the Northern Manhattan Study. Neurol-
ogy, 80(13):1209-1215. DOI: 10.1212/WNL.0b013e3182896e79
Mira Katan, MD
Yeseon Park Moon, MS
Myunghee Cho Paik,
PhD
Ralph L. Sacco, MD, MS
Clinton B. Wright, MD
Mitchell S.V. Elkind,
MD, MS
Correspondence to
Dr. Katan:
mk3270@columbia.edu
Editorial, page 1182
Supplemental data at
www.neurology.org
Infectious burden and cognitive function
The Northern Manhattan Study
ABSTRACT
Objective: We hypothesized that infectious burden (IB), a composite serologic measure of exposure to
common pathogens (i.e., Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes
simplex virus 1 and 2) associated with vascular risk in the prospective Northern Manhattan Study
(NOMAS), would also be associated with cognition.
Methods: Cognitionwas assessed using theMini-Mental State Examination (MMSE) at enrollment and
the modified Telephone Interview for Cognitive Status (TICS-m) at annual follow-up visits. Adjusted
linear and logistic regressions were used to measure the association between IB index and MMSE.
Generalized estimating equation models were used to evaluate associations with TICS-m and its
change over time.
Results: Serologies and cognitive assessments were available in 1,625 participants of the NOMAS
cohort. In unadjusted analyses, higher IB index was associated with worse cognition (change per stan-
dard deviation [SD] of IB for MMSE was 20.77, p , 0.0001, and for first measurements of TICS-m
was 21.89, p , 0.0001). These effects were attenuated after adjusting for risk factors (for MMSE
adjusted change per SD of IB 5 20.17, p 5 0.06, for TICS-m adjusted change per SD IB 5 20.68,
p, 0.0001). IBwas associatedwithMMSE#24 (compared toMMSE.24, adjusted odds ratio 1.26
per SD of IB, 95% confidence interval 1.06–1.51). IB was not associated with cognitive decline over
time. The results were similar when IB was limited to viral serologies only.
Conclusion: A measure of IB associated with stroke risk and atherosclerosis was independently
associated with cognitive performance in this multiethnic cohort. Past infections may contribute
to cognitive impairment. Neurology 2013;80:1209–1215
GLOSSARY
AD5 Alzheimer disease; CI5 confidence interval; CMV 5 cytomegalovirus; GEE 5 generalized estimating equation; HSV 5
herpes simplex virus; IB 5 infectious burden; IQR 5 interquartile range;MMSE 5Mini-Mental State Examination; NOMAS5
Northern Manhattan Study; OR 5 odds ratio; SES 5 socioeconomic status; TICS-m 5 modified Telephone Interview for
Cognitive Status; VIB 5 viral burden index.
Basic and clinical research provide evidence that inflammation triggered by infectious agents may
play a role in the pathogenesis of ischemic stroke,1,2 atherosclerosis,3,4 and dementia.5 Bacterial
and viral infections may invade vessel walls, provoke cytokine release, influence lipid metabolism,
and contribute in other ways to vascular dysfunction. Both viral infections, including herpes simplex
virus type 1 (HSV-1)6 and cytomegalovirus (CMV),7 and bacteria, such as Chlamydia pneumoniae8
and Helicobacter pylori,9 have been associated with cognitive impairment and Alzheimer disease
(AD). In prior analyses of the Northern Manhattan Study (NOMAS), a weighted measure of
infectious burden (IB) including these pathogens was associated with stroke risk and carotid artery
atherosclerosis.2,4
Accumulating evidence suggests that cerebrovascular injury and vascular risk factors are associated
with cognitive decline and increased risk for AD and other dementias.10–14 As the population
continues to age, health care needs associated with treating and caring for elderly individuals with
cognitive decline are projected to pose significant public health and economic burdens.15
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We hypothesized that a measure of chronic
infection incorporating several common infec-
tions (i.e., C pneumoniae, H pylori, CMV, and
HSV-1 and -2) associated with stroke would
also be associated with cognition and cognitive
decline in our stroke-free multiethnic cohort.
METHODS Standard protocol approvals, registrations,
and patient consents. The institutional review boards at
Columbia University Medical Center and the University of
Miami approved the study. All participants gave informed con-
sent to participate in the study.
Description of study population and baseline data
collection. The cohort derived from 3,298 multiethnic stroke-
free participants enrolled in NOMAS between 1993 and 2001,
as previously described.2 Briefly, participants were $40 years of
age at enrollment and resided in northern Manhattan, New York,
for $3 months in a household with a telephone.
Data collection at baseline included vital signs, demographic
data, medical history, vascular risk factors, and clinical laboratory
parameters including glucose levels and fasting lipid levels. In a subset
(n5 984) the number of APOE e4 alleles carried by each subject was
determined by HhaI digestion of PCR products amplified from
genomic DNA. For detailed covariate assessment, see appendix e-1
on the Neurology® Web site at www.neurology.org.
Assessment of IB. Blood samples collected at enrollment were
centrifuged and frozen at 270°C in 1 mL aliquots until the time
of analysis. Since not all participants had blood available for the
measurement of all 5 serologies, a subsample of 1,625 was used for
the present analysis, as previously described.2 Serologies were mea-
sured using ELISA for the following: C pneumoniae (Savyon Diagnos-
tics, Ashdod, Israel), H pylori, CMV (Wampole Laboratories,
Princeton, NJ), and HSV-1 and 2 (Focus Diagnostics, Cypress, CA).
Immunoglobulin G titers were used for all pathogens except C pneu-
moniae, for which immunoglobulin A titers were used based on our
previous results.16,17 All testing was performed in a batch analysis
blinded to clinical outcome.
Cognitive assessment. Cognitive status was assessed at baseline
using the 30-point Mini-Mental State Examination (MMSE)18
and at annual telephone interview follow-up using the modified
Telephone Interview for Cognitive Status (TICS-m).19 Testing
was performed by bilingual trained research assistants in English
or Spanish, depending on language spoken at home.
Statistical analyses. We used IB as the main predictor. Our
development of a weighted IB index based on the relationship
of individual serologic test results to risk of stroke was described
previously.2 In brief, parameter estimates from Cox proportional
hazards model for risk of stroke associated with each serologic
result (positive or negative), adjusted for the other serologies, were
used to derive a weighted index designated as IB. We constructed
models unadjusted and adjusted for demographic and social fac-
tors (age, sex, race-ethnicity, education, and insurance status) and
vascular risk factors (hypertension, diabetes mellitus, cardiac dis-
ease, smoking status, depressive symptoms, reported alcohol con-
sumption, physical activity, cholesterol medication, and lipid
levels). Besides age and high-density lipoprotein, all covariates
were treated categorically. The rationale for choice of covariates
and interactions was based on the literature, biological plausibility,
and previous experience with the cohort. We analyzed MMSE as
both a continuous and binary outcome (MMSE#24 vs.24) based
on previously defined thresholds in order to facilitate clinical
interpretation.20 TICS-m was treated as a continuous variable. We
fitted linear regression with continuous MMSE to calculate the
slope and 95% confidence interval (CI), and logistic regression with
MMSE categories to calculate odds ratio (OR) and 95% CI.
Generalized estimating equation (GEE) models with exchangeable
covariance structure were used to evaluate associations with TICS-m
and its change over time. We tested for interactions between IB and
all demographic or medical risk factors. Moreover, in a post hoc
analysis, we created a viral burden index (VIB) in the same manner
as the overall IB index and tested the association of the VIB index
with cognition.
We used the inverse probability weighted method to correct
for potential selection bias that may have been introduced when
the analyzed group was selected from the whole cohort. All
hypothesis testing was 2-tailed and p values less than 0.05 were
considered significant. All analyses were performed using SAS
v9.1.3 (SAS Institute, Cary, NC).
RESULTS Study population characteristics.The analyzed
population consisted of 1,625 subjects (65% women,
mean age 696 10 years, 58% Hispanic) with serology
measurements (table 1). Characteristics among these
participants were similar to those in the overall NOMAS
cohort.2
Median MMSE was 27 (interquartile range [IQR]
24–29) and median TICS-m over all follow-up meas-
urements was 32 (IQR 27–36). The mean IB index
(6SD) was 1.00 6 0.33 and median 1.08 (IQR
0.91–1.26). The IB index was higher in non-Hispanic
black and Hispanic subjects, and in participants with
less than high school education, no alcohol intake, and
without cardiac disease (table 1).
Association of IB index with MMSE. In unadjusted anal-
ysis, higher IB index was associated with lower MMSE
as a continuous measure (change in MMSE per SD IB
index520.77; p, 0.0001). After adjusting for demo-
graphics and vascular risk factors, the effect was attenu-
ated (change in MMSE per SD IB index 5 20.17;
p 5 0.06).
The IB index was associated with greater odds of
having MMSE #24 compared to MMSE .24
(unadjusted OR per SD IB 5 1.58, 95% CI 1.36–
1.82). The association persisted after adjusting for
demographic and risk factors (adjusted OR per SD
IB 1.26, 95% CI 1.06–1.51; table 2).
In subgroup analyses for those with APOE geno-
type available (n 5 984), we found that the associa-
tion between the IB index andMMSE did not change
after further adjusting for APOE genotype (change in
MMSE per SD of IB index520.20; p5 0.06), and
the effect of the IB index on MMSE did not differ by
APOE genotype (p for interaction 5 0.61).
Association of IB index with TICS-m. There was an
association of higher IB index and impaired cognition
assessed with the TICS-m (difference in baseline
TICS-m per SD IB 5 21.92; p , 0.0001). The
effect was attenuated after adjusting for demographics
1210 Neurology 80 March 26, 2013
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and vascular risk factors, but the association persisted
(adjusted change in baseline TICS-m per SD IB
index 5 20.68; p , 0.0001; table 2). We found no
association, however, of IB with change in TICS-m over
time in analyses either unadjusted or adjusting for
demographics and risk factors (p 5 0.13).
Modification of the association of IB index with cognition.
We found interactions of several baseline risk factors
(i.e., sex, physical activity, education, and insurance
status) with IB index relating to MMSE. The associa-
tions between IB index and MMSE were prominent
among those who were physically inactive (adjusted
change in MMSE per SD IB index 5 20.43; p 5
0.001), women (adjusted change in MMSE per SD
IB index 5 20.32; p 5 0.007), those with Medicaid
or no insurance (adjusted change in MMSE per SD IB
index 5 20.44; p 5 0.003), and those with less than
high school education (adjusted change in MMSE per
SD IB index520.44; p5 0.002), while there were no
associations among their counterparts. Only physical
activity remained an effect modifier when all these inter-
action terms were included in the final model (p for
interaction in the adjusted model 5 0.01).
No interaction of demographic or risk factors with
IB index, however, was found with regard to a change
in TICS-m over time.
Exploratory analyses of viral burden and its association
with cognition. Limiting the IB serologies to viral serolo-
gies (VIB) resulted in similar findings as for the overall IB
index. The VIB index was associated with MMSE#24
compared to MMSE.24 (adjusted OR per SD of VIB
index 5 1.22; p 5 0.04), as well as with TICS-m
(adjusted difference in baseline TICS-m per SD of
VIB index 5 20.70; p , 0.0001), but was not asso-
ciated with change in TIC-m over time (p 5 0.24).
DISCUSSION In this multiethnic population-based
sample, we found that a measure of IB previously asso-
ciated with vascular disease risk is independently associ-
ated with cognitive performance in cross-sectional
analyses. We used well-known and validated measures
of cognitive function. Cognitive status was assessed at
baseline using the 30-point MMSE18 and also during
annual follow-up using the TICS-m.19 These results are
consistent with prior studies identifying an association
between chronic infections and both cognition5–8,21–27
and vascular risk,2–4,28,29 but we further extend prior
findings by using a novel weighted average of IB asso-
ciated with vascular disease risk and by using comple-
mentary measures of cognitive function. Our study
results point to the possibility that the same cumulative
index of pathogens may be a common risk factor for
both stroke and cognitive impairment.
Interestingly, we found a more pronounced asso-
ciation of IB with MMSE when treated as a
Table 1 Baseline characteristicsa
Baseline characteristics of
participants
Subjects
(n 5 1,625)
Median IB index
(IQR) p Valueb
Sociodemographic risk factors
Age, y 68.5 6 10.1 NA NA
Age <70 y 925 (57) 0.91 (1.09–1.26) 0.526
Age ‡70 y 700 (43) 0.91 (1.09–1.26)
Female sex 1,054 (65) 0.91 (1.09–1.26) 0.101
Male sex 571 (35) 0.82 (1.09–1.26)
Non-Hispanic white 295 (18) 0.39 (0.91–1.09) ,0.0001
Non-Hispanic black 333 (21) 0.99 (1.09–1.26)
Hispanic 945 (58) 0.99 (1.09–1.26)
Other 50 (3) NA NA
Education (‡ high school) 708 (44) 0.69 (1.04–1.17) ,0.0001
Education (< high school) 917 (54) 0.99 (1.09–1.26)
Medicaid or no insurance 790 (49) 0.99 (1.09–1.26) ,0.0001
Medicare or private
insurance
829 (51) 0.82 (1.08–1.26)
Vascular risk factors
No physical activity 759 (47) 0.91 (1.09–1.26) 0.079
Any physical activity 866 (53) 0.86 (1.09–1.26)
No depression 1,443 (89) 0.91 (1.09–1.26) 0.205
Depressionc 176 (11) 0.89 (1.09–1.26)
No hypertension 430 (26) 0.82 (1.09–1.26) 0.148
Hypertensiond 1,195 (74) 0.91 (1.09–1.26)
No diabetes mellitus 1,279 (79) 0.86 (1.09–1.26) 0.391
Diabetes mellitus 340 (21) 0.91 (1.09–1.26)
No cardiac disease 1,240 (76) 0.91 (1.09–1.26) 0.043
Cardiac disease 385 (24) 0.86 (1.09–1.26)
No moderate alcohol
intake
1,087 (67) 0.91 (1.09–1.26) 0.044
Moderate alcohol intakee 538 (33) 0.82 (1.09–1.26)
No hypercholesterolemia 590 (36) 0.91 (1.09–1.26) 0.156
Hypercholesterolemia 1,035 (64) 0.86 (1.09–1.26)
No lipid-lowering
medications
1,395 (86) 0.91 (1.09–1.26) 0.060
On lipid-lowering
medications
230 (14) 0.82 (1.08–1.26)
High-density lipoprotein 46.5 6 14.1 NA NA
Never smoker 777 (48) 0.91 (1.09–1.26) 0.559
Past smoker 575 (35) 0.86 (1.09–1.26)
Current smoker 272 (17) 0.86 (1.09–1.26)
Cognitive assessment
MMSE score 27 (24–29) NA NA
MMSE score <24 points 377 (23) 0.99 (1.17–1.26) ,0.0001
MMSE score ‡24 points 1,246 (77) 0.82 (1.08–1.26)
Baseline TICS-m 32 (27–36) NA NA
Continued
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dichotomous variable compared to MMSE as a contin-
uous variable. This might point to a threshold effect or
that only a major change in MMSE is associated with a
higher IB. The use of the 24-point threshold to define
cognitive impairment in Hispanic patients has been a
matter of debate since it is not very well documented
in this ethnic group,20 but this threshold has been used
widely in the literature to describe cognitive impairment
and therefore permits comparison with previous studies.
Additionally, we found that the effect of IB on
cognitive impairment may depend on certain demo-
graphic and vascular risk factors. In general, we found
that the magnitude of effects of IB was greater among
women, those with lower socioeconomic status (lower
levels of education and health insurance), and the phys-
ically inactive. The association was most prominently
modified by participants’ physical activity levels. Among
physically inactive participants, a higher IB index was
associated with a lower MMSE, while there was no
association among physically active participants. This
result should be considered exploratory, however, as
we investigated multiple interactions. Nevertheless, this
observation provides some indirect evidence that the
negative effects of chronic infection might be mitigated
by beneficial behaviors such as physical activity, and
evidence is accumulating that exercise has anti-inflam-
matory effects.30
IB was not associated, however, with cognitive
decline over time, and we did not find any interactions
for this with baseline risk factors. The absence of an asso-
ciation with cognitive decline over time could reflect the
relatively advanced state of cognitive impairment at the
time participants in our relatively elderly cohort were
enrolled, limiting our ability to detect further decline
with time. Our duration of follow-up, moreover, may
have been insufficient to detect a change. Finally, it is
possible that a practice effect, such that participants
improve scores on cognitive tests over time, may have
limited our ability to detect an effect.
Human and animal studies provide evidence that
chronic infections with HSV-1, HSV-2, CMV,
HIV-1, C pneumoniae, and H pylori are associated with
an elevated risk of cognitive impairment and different
forms of dementia.5–8,21–27Most of these previous studies
were focused on one specific pathogen and the few
studies that examinedmultiple pathogens simultaneously
assumed equal weight for each investigated pathogen. For
example, one study investigated 400 randomly selected
home-dwelling individuals with cardiovascular diseases.5
The primary endpoint was cognitive impairment,
defined as MMSE score,24 points at baseline and after
1 year of follow-up. Viral burden at baseline was defined
as the number of seropositivities toward HSV-1, HSV-2,
and CMV equally divided into 3 categories (0 to 1, 2, or
3). The lowest category was a combination because few
people had zero viral seropositivities. Bacterial burden
was defined as seropositivities toward C pneumoniae
and Mycoplasma pneumoniae divided into 3 categories
(0, 1, or 2). Logistic regression was performed with the
categories of viral or bacterial burden, various risk factors,
and demographic data as independent variables. In sub-
jects with 3 viral seropositivities (compared to 1), the
Table 1 Continued
Baseline characteristics of
participants
Subjects
(n 5 1,625)
Median IB index
(IQR) p Valueb
Infectious burden NA NA
IB index 1.00 6 0.33 NA NA
Abbreviations: IB 5 infectious burden; IQR 5 interquartile range; MMSE 5 Mini-Mental
State Examination; NA 5 not applicable; TICS-m 5 modified Telephone Interview for Cog-
nitive Status.
a Values are mean 6 SD, n (%), or median (IQR).
bWilcoxon/Kruskal-Wallis test.
cDepression is defined as a Hamilton Depression Rating Scale score .10 or a history of
antidepressant use.
dHypertension defined by history, taking medications, systolic blood pressure $140 mm
Hg, or diastolic blood pressure $90 mm Hg.
eModerate alcohol intake: one alcoholic drink per week up to 2 drinks per day; sporadic
missing baseline data but not less than n 5 1,619.
Table 2 Association of the infectious burden index with cognitive functiona
Unadjusted Adjusted for demographicsb
Adjusted for demographics,
general, and vascular risk factorsc
MMSE
Difference in baseline MMSE per SD in IB 20.77 (20.95 to 20.58); ,0.0001 20.16 (20.34 to 20.002); 0.08 20.17 (2.34 to 0.01); 0.06
MMSE £24 1.58 (1.36 to 1.82); ,0.0001 1.23 (1.04 to 1.45); 0.019 1.26 (1.06 to 1.51); ,0.01
TICS-m
Difference in baseline TICS-m per SD in IB 21.92 (22.24 to 21.61); ,0.0001 20.66 (20.93 to 20.37); ,0.0001 20.68 (20.97 to 20.39); ,0.0001
Annual change in TICS-m per SD in IB 0.03 (20.01 to 0.07); 0.18 0.03 (20.01 to 0.07); 0.13 0.03 (20.01 to 0.07); 0.13
Abbreviations: IB 5 infectious burden; MMSE 5 Mini-Mental State Examination; TICS-m 5 Telephone Interview for Cognitive Status.
a Values are b coefficient or odds ratios with corresponding 95% confidence interval and p values.
bAdjusted for age, sex, race-ethnicity, education, and insurance status.
c Adjusted for age, sex, race-ethnicity, education, insurance status, depressive symptoms, physical activity, reported alcohol consumption, hypertension,
any cardiac disease, diabetes mellitus, dyslipidemia, high-density lipoprotein, lipid-lowering medication, and smoking status.
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adjusted hazard ratio for cognitive impairment at baseline
was 2.5 (1.3–4.7) and after 1 year it was 2.3 (1.2–4.6).
However, no association was observed between cognition
and bacterial burden. Another investigator studied a sub-
set (n 5 1,204) of the participants in the Sacramento
Area Latino Study on Aging.24 Baseline serum samples
were assayed for levels of immunoglobulin G antibodies
to CMV and HSV-1. Participants were screened annu-
ally over a 4-year period for cognitive function (by
MMSE) and episodic memory (by Delayed Recall Scale
scores). They found a higher rate of cognitive decline over
the 4-year period in subjects with the highest CMV anti-
body levels at baseline than in individuals with the lowest
levels (p 5 0.003). Unlike these studies, we did not
assume that each infection should be associated with a
similar risk of cerebrovascular disease or cognition, and
we implemented a novel weighted average of IB that was
previously associated with cerebrovascular events. How-
ever, since previous studies showed associations primarily
with viruses, we also performed an exploratory analysis to
assess whether the driving force behind the association of
IB index with cognition might be the viral pathogen
burden. The estimates for the associations with cognition
using viral serologies alone were almost identical to those
using a combined bacterial and viral score, providing
support for the notion that most of the effect of IB on
stroke and cognition is mediated through viral rather
than bacterial serologies.
The mechanism for this association remains uncer-
tain. It may be that chronic infection due to these patho-
gens contributes to the overall inflammatory milieu and,
together with other risk factors, leads to atherosclerosis,
subclinical stroke, and dementia. Inflammation in brain
vessels has been postulated to play an important role
in both vascular dementia and AD.31 In addition, a
direct toxic effect of some neurotropic agents may play
a role in the development of cognitive impairment.32,33
Further studies are required to establish the pathogenic
mechanisms.
In our univariate analysis, we found an association
of IB index with insurance status and education,
both proxies for socioeconomic status (SES), as well
as race-ethnicity. In the multivariate analysis after ad-
justing for these demographic variables, the associa-
tion of IB index with cognition was attenuated. It
might be that the known socioeconomic gradients
concerning the incidence of cognitive impairment34
are partly explained by a higher IB.35 For example,
data from the National Health and Nutrition Exam-
ination Survey III addressed socioeconomic and race-
ethnic differences in infection status in the United
States.36 H pylori, CMV, HSV-1, and hepatitis B
virus were used for the infection burden analyses.36
The authors found that individuals with less than
high school education had roughly 50% increased
risk of having an additional infection compared with
high school graduates, whereas those with postsec-
ondary education had 50% lower odds.36 Income
had similar effects, whereby low income was asso-
ciated with 33% higher odds of an additional infec-
tion, and high income with 45% lower odds,
compared with the middle-income group.36 This
association might be due to a higher exposure rate
but it might also be due to an initial susceptibility
to infections triggered by socioeconomic stressors.
There is evidence of an association between low
SES, increased stress, and enhanced susceptibility to
several viruses.37
Our study has limitations. Because it is cross-
sectional, we cannot make conclusions about the direc-
tion of associations. The infections we investigated,
however, most likely preceded the development of cog-
nitive impairment, since the antibody pattern reflects
chronic infectious status and representative studies have
shown that the majority of CMV and HSV-1 infections
occur in childhood.38,39 Second, it was not possible to
examine the relationship between infection and specific
forms of cognitive impairment. For example, earlier
research has shown that CMVDNA is found in a higher
proportion of brains of people with vascular dementia
than in age-matched controls.7 Third, we did not use
detailed neuropsychological testing in our analyses.
However, both the MMSE as well as the TICS-m are
well-established tools to assess cognitive performance in
large cohorts. Fourth, we did not have APOE genotype
information in all subjects. However, in the subgroup
analyses, we found that IB index was independently
associated with cognition even after adjusting for APOE
genotype, and the effects of IB index on cognition did
not differ by APOE genotype. These findings should be
interpreted with caution due to potential selection bias.
Finally, a few factors may have reduced the ability to
detect a strong association between IB index and cogni-
tive decline over time in our study. For example, a mod-
erate practice effect over the follow-up period might
have played a role, or a threshold effect, indicating that
when the damage is already done there is no further
decline.
The strengths of this study include the population-
based multiethnic cohort, including a large proportion
of Hispanic subjects, who are frequently underrepre-
sented in studies of cognition, and the ability to adjust
for numerous potential covariates. In addition, GEE
analyses were used to model corresponding trajectories
of cognitive decline.
Our results need to be validated in independent
populations before they can be generalized. If con-
firmed, however, these findings could have potential
clinical implications. For example, treatment and
eradication of these pathogens might have a positive
impact on cognition as well as stroke, thereby
addressing 2 major causes of neurologic disease
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burden worldwide. In the case of viral pathogens,
early childhood vaccination or antiviral treatment
could decrease stroke risk and cognitive impairment.
Based on our data, early intervention might be more
promising, since there was no association with decline
over time in this elderly cohort.
Our results extend the findings of previous studies
aimed at investigating the association of chronic infec-
tions and cognitive performance and specifically point
to IB as a common risk factor of both stroke and cogni-
tive impairment.
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